Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Healios KKHLOSF 56 EV-to-EBITDA is -11.29 as of Aug. 02, 2026. GuruFocus rates HLOSF with a GF Score™ of 56/100 and a GF Value™ of $0.33 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 416 Biotechnology companies, Healios KK ranks worse than 240384.38% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Healios KK's enterprise value is $147.38 Mil.
Healios KK's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-13.06 Mil. Therefore, Healios KK's EV-to-EBITDA for today is -11.29.
The historical rank and industry rank for Healios KK's EV-to-EBITDA or its related term are showing as below:
HLOSF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -52.48 Med: -20.27 Max: -2.55
Current: -12.11
During the past 12 years, the highest EV-to-EBITDA of Healios KK was -2.55. The lowest was -52.48. And the median was -20.27.
HLOSF's EV-to-EBITDA is ranked worse than 100% of 416
companies
in the Biotechnology industry
Industry Median: 11.905
vs HLOSF: -12.11
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Healios KK's share price for today is $1.80.
Healios KK's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.181.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Healios KK's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HLOSF vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Healios KK's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healios KK EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Healios KK's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Healios KK's EV-to-EBITDA falls into.
Healios KK's current Enterprise Value is $147.38 Mil.
Healios KK's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Healios KK (HLOSF) has a EV-to-EBITDA of -11.29 as of Aug. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Healios KK. According to the industry distribution chart, Healios KK ranks #999999 out of 416 companies in the Biotechnology industry.
Is Healios KK's EV-to-EBITDA too high?
Healios KK's current EV-to-EBITDA is -11.29. Based on the distribution chart, Healios KK ranks #999999 out of 416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Healios KK has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Healios KK's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Healios KK ranks #999999 out of 416 companies for EV-to-EBITDA. This places Healios KK in the lower half of its industry. The industry median EV-to-EBITDA is 11.91. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.91, based on 416 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Healios KK. For the Biotechnology industry, the median EV-to-EBITDA is 11.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Healios KK's current EV-to-EBITDA is -11.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healios KK stock overvalued right now?
Based on GuruFocus' analysis, Healios KK (HLOSF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.33, compared to a current price of $1.80 — trading 445.5% above its estimated fair value. The current EV-to-EBITDA is -11.29. Healios KK's overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Healios KK (HLOSF), the current EV-to-EBITDA is -11.29 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healios KK (HLOSF) Overvalued in 2026?
Based on GuruFocus' analysis, Healios KK stock appears to be overvalued.
The current stock price of $1.80 is trading 445.5% above its estimated GF Value™ of $0.33.
GuruFocus considers Healios KK to be Significantly Overvalued.
Key valuation signals for HLOSF:
EV-to-EBITDA: -11.29
GF Value™: $0.33 vs. price of $1.80 (445.5% above fair value)
No single metric tells the full story. See the HLOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, ischemic stroke, and acute respiratory distress syndrome.
56GF Score
Get the complete analysis for HLOSF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HLOSF has been successfully added to your 
